Showing results (491-500 of 673) with videos related to

Sort By:
Pageof 68
Journal of Global Antimicrobial Resistance|May 13, 2021
Real-life experience with ceftolozane/tazobactam in Canada: results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registryGeorge G Zhanel, Rita Dhami, Melanie Baxter, et al.
Intensive Care Medicine|March 4, 2017
Intensive care medicine research agenda on invasive fungal infection in critically ill patientsMatteo Bassetti, Jose Garnacho-Montero, Thierry Calandra, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|January 9, 2024
Adenovirus infection in adult patients undergoing allogeneic hematopoietic stem cell transplant: Incidence, clinical management, and outcomeElisa Balletto, Marta Ponzano, Anna Maria Raiola, et al.
Critical Care (London, England)|October 29, 2024
Rezafungin versus caspofungin for patients with candidaemia or invasive candidiasis in the intensive care unit: pooled analyses of the ReSTORE and STRIVE randomised trialsPatrick M Honoré, Massimo Girardis, Marin Kollef, et al.
Infectious Diseases and Therapy|June 3, 2024
Opportunities to Enhance Diagnostic Testing and Antimicrobial Stewardship: A Qualitative Multinational Survey of Healthcare ProfessionalsTimothy Jinks, Sumithra Subramaniam, Matteo Bassetti, et al.
Journal of Medical Virology|April 29, 2021
Characterization of T lymphocytes in severe COVID-19 patientsDaniela Fenoglio, Chiara Dentone, Alessia Parodi, et al.
European Journal of Internal Medicine|September 13, 2021
Clinical presentation of secondary infectious complications in COVID-19 patients in intensive care unit treated with tocilizumab or standard of careLucia Taramasso, Laura Magnasco, Federica Portunato, et al.
The Lancet. Infectious Diseases|October 15, 2020
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trialMatteo Bassetti, Roger Echols, Yuko Matsunaga, et al.
The Lancet. Infectious Diseases|December 24, 2019
Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trialMichael S Niederman, Jeff Alder, Matteo Bassetti, et al.
Critical Care (London, England)|June 3, 2014
Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI studyStijn Blot, Despoina Koulenti, Murat Akova, et al.
Pageof 68